$3.52
+0.18 (+5.39%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where QNTM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
4 interventional · 1 with posted results
Held by 2 tracked-famous managers (JANE STREET GROUP, LLC, CITADEL ADVISORS LLC) · FINRA short interest 3.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Assessing the Safety and Efficacy of FSD-F2R6-A-CP in Volunteers in an Induced State of Alcohol IntoxicationNCT06505239IntoxicationRandomized · Triple-masked · Treatment | Not applicable | Completed | Dietary supplement: FSD-F2R6-A-CP, Placebo | Acute Alcohol Intoxication | 26 | 2024-11-07actual | 2025-05-22 |
| Evaluating the Safety, Tolerability, Pharmacokinetics, and Effect of Food of Lucid-21-302 in Healthy VolunteersNCT05821387Single Dose Safety Outcome MeasuresRandomized · Triple-masked · Treatment | Phase 1 | Completed | Drug: Lucid-21-302, Placebo | Healthy Participants | 40 | 2023-07-29actual | 2023-08-29 |
| Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)NCT05652907results2026-04-21Targeted Treatment Effect of 30% Decrease From Baseline to Day 28 in the Average Daily Pain IntensityRandomized · Quadruple-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: For business reasons and not for reasons related to safety or efficacy | Drug: FSD201, Placebo | Mast Cell Activation Syndrome, Mast Cell Activation Disorder Idiopathic | 2 | 2023-05-24actual | 2026-04-21 |
| Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19NCT04619706Percentage of Participants With Disease Progression at Day 28Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Difficulties recruiting new subjects | Drug: FSD201, Placebo · Other: Standard of Care for Covid-19 | COVID-19 | 53 | 2021-08-24actual | 2022-12-05 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19